Natco to sell Sovaldi generics following Gilead deal

03-03-2015

Natco to sell Sovaldi generics following Gilead deal

suphakit73 / Shutterstock.com

India-based generic drug maker Natco Pharma has signed a non-exclusive licensing agreement with Gilead Sciences that allows Natco to make and sell generic versions of hepatitis C drugs including Sovaldi (sofosbuvir), it was announced yesterday (March 2).


Natco Pharma, Gilead Sciences, patent licensing agreement, Sovaldi, hepatitis C, patent, sofosbuvir

LSIPR